Clinical Research Directory
Browse clinical research sites, groups, and studies.
Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA
Sponsor: Shanghai Jiao Tong University School of Medicine
Summary
The purpose of this study is to evaluate the feasibility, efficacy and safety of target therapy according to genomic and proteomic profiling combined with GEMOX in recectable gallbladder carcinoma patients monitored by ctDNA.
Official title: A Multicentre, Open-label, Randomised, Controlled Study of Target Therapy Based on Tumor Molecular Profiling With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA.
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
102
Start Date
2020-06-01
Completion Date
2025-12
Last Updated
2024-10-16
Healthy Volunteers
No
Conditions
Interventions
gemcitabine and oxaliplatin.
GEMOX Conventional chemotherapy:gemcitabine and oxaliplatin.
Afatinib
Target therapy Drug: afatinib
Locations (2)
Renji hospital, Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, China
Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China